Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 13/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28660723 | 1.00 | MEN1 (0.59) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL31325605 | 0.90 | MEN1 (0.65) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL22433824 | 0.87 | CTSK (0.50) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL21312432 | 0.84 | MEN1 (0.57) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL26789194 | 0.84 | MEN1 (0.61) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL25353243 | 0.84 | MEN1 (0.69) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL31040386 | 0.84 | MEN1 (0.65) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL25353238 | 0.84 | MEN1 (0.69) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL2635341 | 0.82 | MEN1 (0.59) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL2635343 | 0.82 | MEN1 (0.59) | MEN1GAAKMT2ACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710687-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-7553975-B2 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7323484-B2 | Farnesyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20060252760-A1 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-11-09 | — | — | US | disclosed |
| US-20060079530-A1 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-04-13 | — | — | US | disclosed |
| US-7022704-B2 | 5,6,7, 8-tetrahydro-imidazo-(1,2a)-pyrazine derivative; useful for treating restenosis and tumor | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2006-04-04 | — | — | US | disclosed |
| EP-0904274-B1 | FARNESYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-6673927-B2 | FOR THERAPY OF TUMOR OR RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2004-01-06 | — | — | US | disclosed |
| US-20030119864-A1 | Farnesyl transferase inhibitors | BIOMEASURE INCORPORATED, A MASSACHUSETTS CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20020013319-A1 | FARNESYL TRANSFERASE INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2002-01-31 | — | — | US | disclosed |
| WO-1997030053-A9 | FARNESYL TRANSFERASE INHIBITORS | — | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079530-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | MEN1 1831/4885GAA 1339/4885KMT2A 3658/4885 |
| US-20060252760-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | MEN1 1831/4885GAA 1339/4885KMT2A 3658/4885 |
| US-20030119864-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | MEN1 1831/4885GAA 1339/4885KMT2A 3658/4885 |
| US-20020013319-A1 | FARNESYL TRANSFERASE INHIBITORS | FNTB, FNTA, LCAT | MEN1 1831/4885GAA 1339/4885KMT2A 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.